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Meiotic maturation of amphibian oocytes induced by progesterone is known to be regulated by protein 
phosphorylation. To investigate a possible role for protein phosphatase-1 in this process, the effect of 
phosphatase inhibitor-2 was determined on the in vivo rate of dephosphorylation of phosphorylase a and 
on the rate of oocyte maturation. Dephosphorylation of microinjected phosphorylase a was inhibited up 
to 40% in the presence of inhibitor-2, with half-maximal inhibition at an intracellular concentration of
0.6 ,uM. Inhibitor-2 also caused over a 3-fold increase in the half-time for maturation, suggesting a possible 
role for protein phosphatase-1 in the regulation of meiosis. 
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1. INTRODUCTION 
As isolated from the ovary, ripe Xenopus oocytes 
in first meiotic prophase are stimulated to com- 
plete meiotic cell division by the addition of pro- 
gesterone in vitro (review [ 1 I). Hormone-stimulated 
oocytes progress to the 2nd meiotic metaphase, 
where they remain physiologically arrested until 
fertilization or activation. These oocytes are very 
large cells (1.4 mm diam.) and suitable for quanti- 
tative microinjection. The use of microinjection 
demonstrated that the signal releasing the oocyte 
from the 1st meiotic arrest is a decrease in activity 
of the cyclic AMP-dependent protein kinase. Thus, 
studies which altered the intracellular level of the 
free catalytic subunit [2] demonstrated that the ob- 
served decrease in cyclic AMP with progesterone 
was both necessary and sufficient to initiate the 
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biological response [2-51. As originally described 
in [6], progesterone inhibits the plasma membrane 
adenylate cyclase by a mechanism involving the 
guanine nucleotide regulatory protein [6-81. Re- 
cent evidence from photoaffinity labelling studies 
indicates that this inhibition of adenylate cyclase is 
mediated by a steroid receptor on the plasma mem- 
brane of the oocyte [9]. 
All of these findings support the hypothesis that 
the prophase arrest of the ripe oocyte is maintained 
by maturation inhibiting phosphoprotein(s), whose 
phosphorylation state is controlled by the cyclic 
AMP-dependent protein kinase [2]. Hence, fol- 
lowing the progesterone-induced inhibition of this 
enzyme, there would be a subsequent reduction in 
the degree of phosphorylation of the putative 
maturation-inhibiting protein(s) [2]. 
The phosphorylation state of any protein is a 
balance between the protein kinase and protein 
phosphatase activities. While it is clear that the 
cyclic AMP-dependent protein kinase activity is 
reduced by progesterone, almost nothing is known 
about the possible involvement of protein phos- 
phatases in the maturation process [I]. An impor- 
tant question, for example, is whether progester- 
Published by Elsevier Biomedical Press 
00145793/82/0000-0000/$2.75 0 Federation of European Biochemical Societies 155 
Volume 150, number 1 FEBSLETTERS December 1982 
one might also increase the rate of dephosphoryla- 
tion of the maturation-inhibiting protein(s) due to 
an increase in protein phosphatase activity. This is 
of particular interest due to the recent findings that 
mammalian protein phosphatases appear to be 
controlled by a variety of hormones [lo- 171. En- 
zymes of one class, termed protein phosphatase-1 , 
have been partially characterized with respect to 
structure and substrate specificity, and are impli- 
cated in the regulation of a number of metabolic 
pathways. Protein phosphatase-1 is inhibited by 
nM levels of two heat-stable proteins termed inhi- 
bitor-l and inhibitor-2 [ 10,20-241, while enzymes 
in the phosphatase-2 class are unaffected by the in- 
hibitors [ 10, 11,18,19]. Inhibitor-l is inhibitory 
only when phosphorylated by the cyclic AMP-de- 
pendent protein kinase [20-241, while inhibitor-2 
does not require phosphorylation [23,24]. Inhibi- 
tor-l and inhibitor-2 have been shown to act as 
specific inhibitors of protein phosphatase-1 in a va- 
riety of mammalian tissue extracts [18-201, and 
the phosphorylation state of inhibitor-l is control- 
led in vivo by both epinephrine [12-141 and insulin 
[ 131. However, a conclusive demonstration that 
these proteins act as phosphatase inhibitors in vivo 
has not been made, nor has it been determined in 
a single cell what proportion of phosphorylase 
phosphatase is accounted for by the protein phos- 
phatase-1 class. Furthermore, several reports 
[25-271 have led to the claim that protein 
phosphatase-1 is not present in ‘fresh’ tissue ex- 
tracts, suggesting that the enzyme is artifactually 
generated by proteolysis during homogenization. 
In this paper, studies with inhibitor-2 are presented 
which suggest that protein phosphatase-1 isan acti- 
ve phosphorylase phosphatase in both oocyte ex- 
tracts and in vivo in the intact living oocyte. 
Inhibitor-2 was also used as a probe to investigate 
a possible role for protein phosphatase-1 in the 
control of oocyte maturation. The results of these 
experiments are discussed in relation to the activity 
of protein phosphatase-1 in vivo. 
2. MATERIALS AND METHODS 
2.1. Isolation of oocytes and microinjection 
Xenopus laevis females were primed with 35 IU 
pregnant mare’s serum gonadotropin 3 days prior 
to decapitation and removal of ovaries. Oocytes 
were manually dissected from the ovarian follicle 
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with watchmaker’s forceps. Detailed procedures 
for isolation of oocytes, preparation and calibra- 
tion of micropipets are described in [28]. 
2.2. Preparation of inhibitor-2 andphosphorylase a
Inhibitor-2 was prepared from rabbit skeletal 
muscle and assayed as in [23]. Prior to microinjec- 
tion, the inhibitor was diluted in buffer A (10 mM 
Tris, 0.01% Brij 35, pH 7.0). Units of inhibitor-2 
and protein phosphatase-1 activity are as in [23]. 
The purified material had spec. act. 83000 
units/mg, corresponding to an 87% homogenous 
preparation [23]. Assays confirmed the inhibitor-2 
preparation was free of the heat-stable inhibitor of 
the cyclic AMP-dependent protein kinase. All con- 
centrations of inhibitor-2 inside the oocyte are 
based on 1~1 cell water and assume homogenous 
distribution of material after injection. 32P-label- 
led phosphorylase a was prepared as in [29], and 
stored at 0°C in 50 mM Tris-HCl, 1 mM EDTA, 
100 mM NaCl, 20% ethanediol, 30 mM mercapto- 
acetic acid (pH 7.4). [Y-~*P]ATP was synthesized 
as in [30]. Protein was determined as in [31]. 
2.3. Oocyte maturation 
Maturation was induced by exposure of oocytes 
to progesterone (10 pg/ml) in medium OR2 [32] 
followed by incubation at room temperature. A 
maturation response was assessed by the frequency 
of germinal vesicle breakdown as evidenced by a 
white spot in the animal pole and confirmed by 
manual dissection of oocytes fixed in 5% trichloro- 
acetic acid. 
2.4. Determination of phosphorylase phosphatase 
activity in vitro 
Thirty oocytes were dropped into 0.4 ml 250 mM 
sucrose, 4 mM EDTA, 15 mM ,&mercaptoethanol, 
20 mM Tris-HCl (pH 8.0, 4’C) and homogenized 
in a Dounce hand homogenizer. The suspension 
was centrifuged for 40min at 7000 x g, at 4°C. 
The supernatant was decanted and then centrifuged 
(1500 x g, 4 min) through a Sephadex G-50 (fine) 
column (6.5 x 0.7 cm), equilibrated in 50 mM 
Tris-HCl (pH 7.6, 4”C), 1 mM EDTA, 30 mM 
,&mercaptoethanol (buffer B). The gel-filtered ex- 
tract was diluted 60-fold before assay into buffer 
B containing 6mM MnC12 and 1 mg bovine serum 
albumin/ml. Assays were done at 30°C. Details of 
the phosphorylase phosphatase assay are in [23]. 
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2.5. Determination of phosphorylase phosphatase 
activity in vivo 
Oocytes (15-30) were individually injected with 
50-60 ml [32P]phosphorylase a (> 2000 cpm) with 
or without inhibitor-2. The zero time of the reac- 
tion was taken immediately after all the injected 
material had entered the cell. The reaction was ter- 
minated by dropping oocytes into 1 ml ice cold 
10% trichloroacetic acid; 0.1 ml 20 mg bovine 
serum albumin/ml was then added, followed by 
centrifugation in a microcentrifuge and liquid scin- 
tillation counting of the soluble and insoluble frac- 
tion. In some cases where longer incubation times 
were employed, several oocytes were injected over 
a 30 s interval and the zero time of the reaction 
taken as the half-time for completion of the injec- 
tion. The time between the first and last oocyte of 
a group being injected never amounted to >lO% of 
the total assay time. All experiments were carried 
out at least 3 times. All values shown are the mean 
of duplicate determinations on oocytes from the 
same female. 
3. RESULTS AND DISCUSSION 
In the presence of 1 mM Mn*+ to optimise total 
phosphatase activity, the specific activity of phos- 
phorylase phosphatase in the oocyte extracts was 
1.35 & 0.16 (n = 6) units/mg protein, a level of 
activity comparable to that reported for a variety 
of mammalian extracts [ 18,191. Phosphorylase 
phosphatase activity in such extracts is attributed 
to the action of both protein phosphatase classes 1 
and 2 [ 11,181. In the presence of 100 units inhibi- 
tor-2, 26 f 4% (n = 6) inhibition was observed in 
the oocyte extract, indicating that -25% of the 
activity was due to protein phosphatase-1, and 
75% to protein phosphatase-2 (the inhibitor-2 in- 
sensitive activity). This is similar to the levels of 
these enzymes in rabbit liver extracts [18-201. The 
dephosphorylation of phosphorylase a proceeds in 
a linear fashion with time after injection into the 
oocyte, and the rate is significantly reduced in the 
presence of inhibitor-2 (fig. 1). Buffer A alone had 
no effect. To determine whether the inhibition was 
saturable, dose-response curves were carried out 
with increasing concentrations of inhibitor-2 in- 
jected in a constant volume (60 nl), with a constant 
amount of phosphorylase a. Inhibition was satur- 
able, with half-maximal inhibition at an internal 
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Fig. 1. Effect of inhibitor-2 on the dephosphorylation f 
phosphorylase a in vivo. [32P]Phosphorylase CI was 
mixed with an equal volume of buffer A; (10 mM Tris, 
0.01% Brij-35, pH 7.0) (c--+) or inhibitor-2 (o---o) 
and the rate of dephosphorylation after microinjection 
determined as in section 2. The final concentration of 
inhibitor-2 in the cytoplasm was -4 pM. 
concentration of 0.6 PM inhibitor-2 (fig. 2). This is 
similar to the concentration of inhibitor-2 in rabbit 
skeletal muscle, 0.35 pM [23]. Saturating concen- 
trations of inhibitor-2 resulted in a 40% decrease in 
the rate of phosphorylase a dephosphorylation, 
demonstrating unambiguously that inhibitor-2 can 
act as a phosphatase inhibitor in vivo. 
The fact that inhibitor-2 acts as a saturable in- 
hibitor of phosphorylase phosphatase in the intact 
oocyte suggests that only one class of phosphatase 
in the oocyte is subject to inhibition by inhibitor-2. 
We suggest hat the inhibited activity corresponds 
to protein phosphatase-1. The possibility that the 
non-inhibited activity represents proteolysis has 
been ruled out by demonstrating all radioactivity 
released comigrates with Pi on thin-layer chroma- 
tography. 
To determine whether protein phosphatase-1 
acts on the putative maturation-inhibiting phos- 
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Fig. 2. Dose-response curve for inhibition of dephos- 
phorylation of phosphorylase a in vivo. Oocytes (10-30) 
were injected with 60 nl [32P]phosphorylase a (>2000 
cpm) containing increasing concentrations of inhibi- 
tor-2. After 3 min, the reaction was terminated and the 
extent of dephosporylation determined as in section 2. 
The abscissa represents the intracellular concentration of 
inhibitor-2 in units/ml; 1500 units/ml corresponds to a 
concentration of -0.6 ,uM [23]. 
phoprotein(s), single doses of increasing concen- 
trations of inhibitor-2 were injected into oocytes, 
followed by progesterone administration. It was 
anticipated that if protein phosphatase-1 played an 
obligatory role during initial progesterone action, 
then injection of inhibitor-2 should block matura- 
tion. Inhibitor-2 was capable of delaying, in a 
dose-dependent fashion, the time required for 
germinal vesicle breakdown (fig. 3). Apparently 
saturating concentrations of inhibitor-2 delayed 
the half-time for 50% of the oocytes to undergo 
germinal vesicle breakdown by >3-fold. Half- 
maximal effects were seen at an internal concentra- 
tion of 2.0 PM inhibitor-2. If the steady state level 
of a maturation-inhibiting phosphoprotein can be 
rapidly affected by changes in phosphatase activity 
and protein phosphatase-1 was the only phospha- 
tase acting at this step, one might have predicted, 
a priori, that inhibitor-2 would have completely in- 
hibited maturation, as seen with microinjection of 
catalytic subunit of cyclic AMP-dependent protein 
kinase [ 1,2], Complete inhibition is not observed 
with inhibitor-2 which suggests, but does not 
! nllllll’lll .- 
” 
2 4 6 8 IO 12 I4 16 18 20 
Fig. 3. Effect of inhibitor-2 on oocyte maturation. 
Groups of 25-30 oocytes were injected with increasing 
concentrations of inhibitor-2 prior to progesterone 
stimulation, and the time course for germinal vesicle 
breakdown determined. Controls were injected with 
buffer A. Progesterone (10 ,uM) was administered 
15-30 min after injection of inhibitor-2, 0.5 GVBD 50 
represents 50% of the time required for 50% of the 
responding oocytes to undergo germinal vesicle break- 
down. The abscissa represents the final intracellular con- 
centration of inhibitor-2 in units/ml. 
prove, that the hormonal control of the steady state 
level of the maturation-inhibiting phosphopro- 
tein(s) is not controlled primarily by changes in 
phosphatase-1 activity. However, several other ex- 
planations for incomplete inhibition of maturation 




More than one protein phosphatase could be 
involved, with the second enzyme being insen- 
sitive to inhibitor-2. The existence of such an 
enzyme(s) is indicated in fig. 2 and, in addi- 
tion, Ca2+ also regulate oocyte maturation [ 11, 
and we have found significant levels of a 
calcium/calmodulin-dependent protein phos- 
phatase-2 [33] in oocytes (unpublished). 
The kinetics of inhibition in vitro indicate that 
inhibitor-2 acts in a hyperbolic manner, sug- 
gesting that complete inhibition would be dif- 
ficult to achieve; 
Inhibitor-2 may be inactivated with time, 
either by proteolysis, or perhaps in a more 
physiologically relevant manner [34,35]. 
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While this work was in progress, it was reported 
that microinjection of the phosphorylated form of 
inhibitor-l could also delay but not prevent 
maturation [36], similar to the results presented 
here for inhibitor-2. Failure to totally block ma- 
turation was interpreted as being due to a dephos- 
phorylation of inhibitor-l. Clearly this cannot pro- 
vide an explanation for the similar effects observed 
here with inhibitor-2. The ability of inhibitor-l and 
inhibitor-2 to delay maturation supports the con- 
cept that phosphatase-1 could be involved in 
oocyte maturation. The resting activity of phos- 
phatase-1 might become regulatory only in the 
event of reduced protein kinase activity with pro- 
gesterone, or there could be a net activation of the 
phosphatase. Conclusive evidence for this latter 
possibility will require the demonstration that this 
enzyme is activated in response to progesterone, 
possibly after inhibitor-l dephosphorylation. 
These considerations also lead to the prediction 
that microinjection of purified protein phospha- 
tase-1 alone would be sufficient to initiate the 
maturation response. These predictions are cur- 
rently under investigation in order to evaluate the 
possibility that inhibitor-l is in fact one of the 
maturation inhibiting phosphoproteins. 
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